Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene therapy for familial hypercholesterolemia.

D J Rader1

  • 1Departments of Medicine, Pathology and Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA. rader@mail.med.upenn.edu

Nutrition, Metabolism, and Cardiovascular Diseases : NMCD
|June 18, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A catalog of associations between rare coding variants and COVID-19 outcomes.

medRxiv : the preprint server for health sciences·2021
Same author

Genome-wide analysis in 756,646 individuals provides first genetic evidence that <i>ACE2</i> expression influences COVID-19 risk and yields genetic risk scores predictive of severe disease.

medRxiv : the preprint server for health sciences·2021
Same author

Development and feasibility of quantitative dynamic cardiac imaging for mice using μSPECT.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology·2020
Same author

Deletion of murine Arv1 results in a lean phenotype with increased energy expenditure.

Nutrition & diabetes·2015
Same author

The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.

Atherosclerosis·2015
Same author

High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm.

Clinical pharmacology and therapeutics·2014

Gene therapy shows promise for treating homozygous familial hypercholesterolemia (FH). Preclinical studies demonstrate potential for long-term expression of key receptors, reducing LDL cholesterol and atherosclerosis, paving the way for clinical trials.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Therapy
  • Metabolic Disorders

Background:

  • Familial hypercholesterolemia (FH) is a genetic disorder characterized by extremely high LDL cholesterol levels.
  • Homozygous FH presents a severe, early-onset form of the disease with limited treatment options.
  • Current therapies for homozygous FH are often suboptimal, highlighting the need for novel approaches.

Purpose of the Study:

  • To evaluate the potential of gene therapy for treating homozygous familial hypercholesterolemia (FH).
  • To assess the feasibility of long-term expression of LDL and VLDL receptors via gene therapy in preclinical models.
  • To determine the impact of such gene therapy on LDL cholesterol levels and atherosclerosis progression.

Main Methods:

  • Preclinical studies were conducted in relevant animal models of homozygous FH.

Related Experiment Videos

  • Gene therapy vectors were developed to achieve long-term expression of the low-density lipoprotein (LDL) receptor and the very low-density lipoprotein (VLDL) receptor.
  • The efficacy of gene therapy was assessed by measuring reductions in LDL cholesterol and atherosclerosis.

    • Main Results:

    • Preclinical proof-of-principle studies demonstrated successful long-term expression of both LDL and VLDL receptors.
    • These studies showed significant reductions in LDL cholesterol levels in the treated animal models.
    • Atherosclerosis burden was also reduced, indicating a positive therapeutic effect.

    Conclusions:

    • Gene therapy represents a promising therapeutic strategy for homozygous familial hypercholesterolemia (FH).
    • The development of safe vectors for long-term gene expression is crucial for clinical translation.
    • Successful gene therapy for homozygous FH is anticipated once advanced vector technology becomes available.